Journal
CURRENT CANCER DRUG TARGETS
Volume 23, Issue 7, Pages 564-571Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009623666230215142941
Keywords
Hepatocellular carcinoma; transarterial chemoembolization; hepatic arterial infusion chemotherapy; tyrosine kinase inhibitor; triple-therapy; unresectable
Categories
Ask authors/readers for more resources
This study evaluated the efficacy and safety of combining transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) and a tyrosine kinase inhibitor (TKI) for the treatment of unresectable large hepatocellular carcinoma (HCC). The results showed that this triple therapy regimen was well-tolerated and showed promise in treating large, unresectable HCC.
Objective Evaluate the efficacy and safety of transarterial chemoembolization (TACE) sequential with hepatic arterial infusion chemotherapy (HAIC) and a tyrosine kinase inhibitor (TKI) for unresectable large hepatocellular carcinoma (HCC). Methods Patients with HCC size > 70 mm were included. They received 1-3 cycles of TACE and sequential HAIC every 3-6 weeks for 2-6 cycles, with each cycle given over a period of 48 hours (oxaliplatin plus fluorouracil/leucovorin). Patients also received sorafenib or lenvatinib beginning at the first TACE cycle and continuing until disease progression. Objective response rate (ORR) at 3 months was the primary endpoint. Progression-free survival (PFS) and safety were the secondary endpoints. Results From January 2020 to December 2020, 41 patients were included, who were divided into the drug-eluting bead TACE (DEB-TACE) group (n=13) and conventional TACE (cTACE) group (n=28). The overall ORR was 56.1% (23/41) using mRECIST criteria and 34.1% (14/41) using RECIST1.1 criteria. The median PFS of the cohort was 8 months. The ORR of the DEB-TACE group was 76.9% (10/13) vs. 46.4% (13/28) for the cTACE group (p = 0.06). The median PFS of the DEB-TACE group was 12 months, and 6 months in the cTACE group (p = 0.09). Conversion hepatectomy was performed in 2 patients in the DEB-TACE group (15.4%), and in 3 patients in the cTACE group (10.7%). ALT/AST elevated, hypertension, nausea, and vomiting were the common treatment related adverse events. There was no treatment related death. Conclusion TACE sequential with HAIC combined a TKI is a well-tolerated and promising triple-therapy for large, unresectable HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available